Lilly's Cyramza Gets FDA Nod for Second-Line Liver Cancer


Lilly's Cyramza Gets FDA Nod for Second-Line Liver CancerLilly's (LLY) Cyramza gets FDA approval to treat AFP-high hepatocellular carcinoma (HCC), a common form of liver cancer. FDA removes boxed warning from label.



Tags: Science, Fda, Afp, Lilly, HCC

Source:  https://news.yahoo.com/lillys-cyramza-gets-fda-nod-134601988.html